R. Janet Whitmore - 31 Dec 2024 Form 4 Insider Report for NANOPHASE TECHNOLOGIES Corp (NANX)

Role
Director
Signature
/s/ Jess Jankowski, Under UPA for R. Janet Whitmore
Issuer symbol
NANX
Transactions as of
31 Dec 2024
Transactions value $
$29,280
Form type
4
Date filed
13 Jan 2025, 17:35
Previous filing
05 Nov 2024
Next filing
11 Dec 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NANX Common Stock 2.05M 31 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NANX Common Stock (Right to Buy) Award $29.3K +12K $2.44 12K 31 Dec 2024 Common Stock 12K $2.44 Direct F5
holding NANX Deferred Common Stock 20K 31 Dec 2024 Common Stock 20K Direct F1, F2, F3
holding NANX Common Stock (right to purchase) 2K 31 Dec 2024 Common Stock 2K $1.85 Direct F4
holding NANX Common Stock (right to purchase) 20K 31 Dec 2024 Common Stock 20K $4.17 Direct F5
holding NANX Common Stock (right to purchase) 13.3K 31 Dec 2024 Common Stock 13.3K $1.17 Direct F5
holding NANX Common Stock (right to purchase) 12.6K 31 Dec 2024 Common Stock 12.6K $0.61 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of deferred common stock represents the right to receive one share of common stock.
F2 The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.
F3 Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 20,030 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensaion Plan.
F4 The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued at identical exercise prices to the conversion prices of the respective stock appreciation rights. These 2000 shares were issued with an exercise price of $1.85.
F5 Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.

Remarks:

This report is being filed late due to an administrative error on the part of the Company. Ms. Whitmore received this grant of stock options as part of the Company's annual equity compensation practices.